TRIDEXIN-

Main information

  • Trade name:
  • TRIDEXIN GLUCOCORTICOID INJECTION
  • Available from:
  • VR
  • Pharmaceutical form:
  • PARENTERAL LIQUID/SOLUTION/SUSPENSION
  • Units in package:
  • 50mL
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • JUROX

Documents

Localization

  • Available in:
  • TRIDEXIN GLUCOCORTICOID INJECTION
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CALF | CATTLE | HORSE | HORSE FOAL | PIGS | BEEF | BEEF CALF | BOAR | BOS INDICUS | BOS TAURUS | BOVINE | BUFFALO | BULL | BULLO
  • Therapeutic area:
  • corticosteroid
  • Therapeutic indications:
  • CORTICOSTEROID | ADVANCING PARTURITION | ALLERGIC REACTIONS | ANTIADRENAL SUPPRESSION | ANTI-INFLAMMATORY | ANTISHOCK | ARTHRITIS | BRONCHITIS | CATABOLIC COMPLICATIONS | CHRONIC BRONCHITIS | CORTICOSTEROIDS | CORTICOSTEROIDS AND RELATE | COUGHS | DERMATITIS | DERMATOLOGICAL DISORDERS | DERMATOSES | ECZEMA | GLUCOGENIC STEROID | JOINT DISEASE | KETOSIS | LOCOMOTIVE DISEASES | MUSCULO SKELETAL INFLAMMAT | ORTHOPAEDIC | PARTURIENT UDDER OEDEMA | PARTURITION | PRURITIS | RESPIRATORY TRACT DISEASES | RHEUMATIC DISEASES | STRESS | TOXAEMIA | WATER RETENTION
  • Product summary:
  • For the suppression of inflammation in dermatological, arthritic and infectious conditions. For the induction of bovine parturition.

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered but not available
  • Authorization number:
  • 36251/0408
  • Authorization date:
  • 06-05-2008
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

Info

pest

Verified

18-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Levofloxacin / dexamethasone, decision type: , therapeutic area: , PIP number: P/0277/2018

Opinion/decision on a Paediatric investigation plan (PIP): Levofloxacin / dexamethasone, decision type: , therapeutic area: , PIP number: P/0277/2018

Opinion/decision on a Paediatric investigation plan (PIP): Levofloxacin / dexamethasone, decision type: , therapeutic area: , PIP number: P/0277/2018

Europe - EMA - European Medicines Agency

22-11-2018

Ozurdex (Allergan Pharmaceuticals Ireland)

Ozurdex (Allergan Pharmaceuticals Ireland)

Ozurdex (Active substance: dexamethasone) - PSUSA - Modification - Commission Decision (2018)7886 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1140/PSUSA/985/201801

Europe -DG Health and Food Safety

24-9-2018

Neofordex (Laboratoires CTRS)

Neofordex (Laboratoires CTRS)

Neofordex (Active substance: dexamethasone) - Centralised - Yearly update - Commission Decision (2018)6239 of Mon, 24 Sep 2018

Europe -DG Health and Food Safety